Themis Medicare Ltd
NSE: THEMISMED BSE: 530199
₹85.80
(-1.20%)
Wed, 11 Mar 2026, 03:15 am
Market Cap7.95B
PE Ratio0
Dividend0.58
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1969
- Themis Chemicals Limited was incorporated as a Limited Company in the form of a Joint Venture between M/s Chemosyn Private Limited and Medimpex Trading Company Ltd.
1971
- TCL started manufacturing Vitamin B12 using anaerobic, non-sterile fermentation technology.
1983
- Mr. Shantilal D. Patel and Mr. K.T. Lakdawala took over the management of the Company.
- The Company started being managed by Dr. Dinesh S. Patel, Mrs. Jayashree D. Patel, and other professionals.
1994
- The Company ranked fourth in terms of turnover in the antituberculosis market according to the ORG Retail Survey Audit.
2000
- The Company proposed to change its name from Themis Chemicals Limited to Themis Medicare Limited.
2004
- The Company completed the merger of Artemis Biotech with itself.
- Themis Medicare Ltd and Gedeon Richter Ltd signed an agreement to establish a Company for manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates.
2005
- Themis Medicare Ltd signed an Agreement with M/s. Darou Pakhsh Pharma Chem. (DPPC) of Iran.
2006
- Themis Medicare commenced formulation production at its new manufacturing unit at Haridwar.
2007
- Themis Medicare developed a global first-of-its-kind product, Aceclofenac Injection.
- The Company entered into an agreement with M/S Darou Pakhsh Pharma Chem, Iran, for establishing a manufacturing facility for Statins in Iran.
- The company designed an E-mail ID for Investor Complaints.
2008
- Themis Medicare recommended a dividend of 25%.
2009
- The Board of Directors appointed Shri. Rajneesh Anand as an Additional Director.
2010
- Themis Medicare launched a combination of Lidocaine & Prilocaine in 'Spray' form under the brand name 'Lovelong'.
2011
- Themis Medicare introduced a 'calcium' preparation with fruity gummies for pediatric use under the brand name 'THEMIBEAR'.
- Themis Medicare introduced a 'Multivitamin' for pediatric use under the brand name 'THEMIBEAR'.
- Themis Medicare launched the brand LUMIXYL, entering the COSMETO-DERMATOLOGY segment.
2013
- Themis Medicare Limited entered into a License and Supply Agreement with Novartis India Limited to supply Diclofenac topical gel.
- Themis Medicare Ltd entered into a Supply & Distribution Agreement with Novartis India Ltd to supply Diclofenac Sodium 75mg per ml Injection.
2014
- Themis invented Aquadol Spass 1ml Injection and commenced production, marketing, and sales.
2022
- Inosine Pranobex, a unique Immunomodulator drug, received use approval from The Drug Controller General of India for the treatment of COVID-19.
2023
- The Company has split its face value from Rs. 10/- to Rs. 1/-.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800